14.45 | 11.45 Liquid Biopsy Assay Screening : A Payor’s Perspective

Time: 2:45 pm
day: Day Three


  •  The critical importance of assay sensitivity and specificity to act as a decision maker, not descriptive assets
  • How can clinical utility of translational genomics be better demonstrated to payors?
  • Kaiser Permanente assay approval process: what are payors looking for to cover assays within policy?
  • Where are cell free tumor DNA assays most needed clinically?